thiophenes has been researched along with Stroke in 393 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 38 (9.67) | 29.6817 |
2010's | 347 (88.30) | 24.3611 |
2020's | 8 (2.04) | 2.80 |
Authors | Studies |
---|---|
Ahmed, HA; Alshammari, A; Althomali, W; Awad, ME; Cooley, MA; Dong, G; Eldahshan, W; Elsalanty, M; Ergul, A; Fagan, SC; Gillis, E; Jackson, L; Pillai, B; Sayed, MA; Sullivan, JC | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Carnicelli, AP; Fox, KAA; Halperin, JL; Hankey, GJ; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
Ding, HY; Jiao, Z; Liu, XQ; Ma, CL; Yan, MM; Zhang, YF; Zhong, MK | 1 |
Ahmed, HA; Devlin, P; Ishrat, T; Ismael, S; Liao, FF; McDonald, MP; Salman, M | 1 |
Ahmed, HA; Ergul, A; Fagan, SC; Fouda, AY; Hardigan, T; Ishrat, T; Kozak, A; Pillai, B | 1 |
Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z | 1 |
Takahashi, T | 1 |
Althomali, W; Baban, B; Dong, G; Eldahshan, W; Ergul, A; Fagan, SC; Filosa, J; Jackson, L; Johnson, MH; Sayed, MA | 1 |
Yavelov, IS | 1 |
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
Fang, X; Ni, HF; Tong, KZ; Wang, X | 1 |
Chen, G; Chen, X; Cheng, Y; Cui, Y; Cui, Z; Li, P; Li, Q; Liu, Z; Yao, L; Zhang, F; Zhang, K; Zhang, N; Zhang, S | 1 |
Hu, Y; Huang, S; Tang, L | 1 |
Bennion, DM; Dang, AN; Domenig, O; Graham, JT; Isenberg, J; Jones, CH; Lindblad, L; Poglitsch, M; Steckelings, UM; Sumners, C; Waters, MF | 1 |
Ahmed, H; Eldahshan, W; Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Pillai, B; Waller, JL | 1 |
Abe, H; Goshima, Y; Higo, N; Jitsuki, S; Jitsuki-Takahashi, A; Katsuno, Y; Komori, T; Masuyama, H; Mochizuki, N; Murata, Y; Nakajima, W; Okuda, T; Sano, A; Suyama, K; Tada, H; Takahashi, T | 1 |
Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
Ahmed, HA; Bunting, KM; Ergul, A; Fagan, SC; Ishrat, T; Pillai, B; Vazdarjanova, A; Waller, JL | 1 |
Anticoli, S; Dalmaso, SG; Marchitto, N; Pannozzi, A; Raimondi, G; Sindona, F | 1 |
Boujon, V; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Uhlemann, R; Wegner, S; Wright, MB | 1 |
Barrios, V; Escobar, C | 1 |
Akwaa, F; Spyropoulos, AC | 1 |
Galanis, T; Merli, GJ | 1 |
Berman, JP; Halperin, JL | 1 |
Lenchus, JD | 1 |
Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
Hernández, M; Suárez, C | 1 |
Masjuan, J | 1 |
Dalmau, FG | 1 |
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Pan, G; Patel, MR; Piccini, JP; Singer, DE | 1 |
Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
Chen, W; Geng, Y; Hu, XY; Wei, LL; Yao, LY; Zhang, JH; Zhang, LS | 1 |
Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
Cayabyab, FS; Gowribai, K; Walz, W | 1 |
Harris, K; Mant, J | 1 |
Atarashi, H | 1 |
Darius, H; Sommer, S | 1 |
Ahmad, Y; Lip, GY | 2 |
Gallego, P; Lip, GY; Roldan, V | 1 |
Carter, NJ; Plosker, GL | 1 |
Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
Bauer, KA | 1 |
Aisenberg, J; Desai, J; Granger, CB; Weitz, JI | 1 |
Klein, HH | 1 |
Toth, PP | 1 |
Apostolakis, S; Lip, GY; Shantsila, E | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hannan, KL; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Schwabe, K; Singer, DE | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; White, HD; Wojdyla, D | 1 |
Gong, IY; Kim, RB | 1 |
Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
Boos, CJ; Camm, AJ; Nam, M | 1 |
Finsterer, J; Stöllberger, C | 5 |
Diener, HC | 1 |
Lopes, RD; Newby, LK; Truffa, AA | 1 |
Bhimani, AA; Hong, M | 1 |
Geller, BJ; Gibson, CM; Guo, J; Hoffman, EB; Mega, JL; Morrow, DA; Ruff, CT | 1 |
Opolonskaia, NA; Tseluĭko, VI; Vashakidze, ZS | 1 |
Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
Aguilar, MI; Freeman, WD; Kuo, RS | 1 |
Delgado-Fernández, M | 1 |
Hori, M; Kajikawa, M | 1 |
Dalen, JE | 1 |
Fanikos, J | 1 |
Li, C; Li, T; Mao, L; Yuan, K | 1 |
Wanat, MA | 1 |
Baglin, T | 1 |
Stiefelhagen, P | 1 |
Barry, M | 1 |
Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD | 1 |
Lip, GY; Potpara, TS | 1 |
Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
Goto, S; Hori, M; Iekushi, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H; Yamanaka, S | 1 |
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A | 1 |
Apostolakis, S; Banerjee, A; Lane, DA | 1 |
Becker, RC; Breithardt, G; Califf, RM; Chang, Y; Fox, KA; Go, AS; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 2 |
Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
Asukai, Y; De Ruyck, M; Evers, T; Faes, P; Goethals, M; Kleintjens, J; Li, X; Rietzschel, ER; Saka, Ö; Simoens, S; Thijs, V; Vansieleghem, S | 1 |
He, B; Kun, L; Liu, X; Wu, B | 1 |
Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
Gunalingam, B; Markus, R; Spina, R; Subbiah, R | 1 |
Kornej, J; Lip, GY; Potpara, T | 1 |
Anisimova, AV; Borisov, SN; Gendlin, GE | 1 |
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD | 1 |
Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
Eikelboom, JW; Kapral, MK; McGrath, ER; O'Donnell, MJ | 1 |
Nagatsuka, K; Okata, T; Takasugi, J; Toyoda, K; Yamagami, H | 1 |
Alonso-Canovas, A; Alvarez-Velasco, R; de Felipe Mimbrera, A; Kawiorski, MM; Masjuan, J; Sainz de la Maza, S; Zarza, B | 1 |
Wood, P | 1 |
Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD | 1 |
Manning, JA | 1 |
Kitazono, T | 1 |
Uchiyama, S | 1 |
Laffan, M; Shapiro, S | 1 |
Breithardt, G; Califf, RM; Fox, KA; Halperin, J; Hankey, GJ; Hellkamp, AS; Jones, WS; Mahaffey, KW; Patel, MR; Piccini, JP; Singer, DE | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; White, HD; Wojdyla, DM | 1 |
Heitmeier, S; Jenetzky, E; Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A | 1 |
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B | 1 |
Barillari, G; Cheng, JW | 1 |
Archeval-Lao, JM; Bowry, R; Cai, C; Fraser, S; Grotta, JC; Parker, SA; Rahbar, MH | 1 |
Diener, HC; Weber, R | 1 |
Caldeira, D; Costa, J; Ferreira, JJ; Pinto, FJ | 1 |
Bajorek, B; Wang, Y | 1 |
Schulman, S | 1 |
Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX | 1 |
Hanon, O | 1 |
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A | 1 |
Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H | 1 |
Bennion, DM; Desland, F; Joseph, JP; Katovich, MJ; Mecca, AP; Patel, NA; Pioquinto, DJ; Regenhardt, RW; Rodríguez, V; Steckelings, UM; Sumners, C; Unger, T | 1 |
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA | 1 |
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
Becker, RC; Califf, RM; Douketis, JD; Fox, KA; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; Spyropoulos, AC | 1 |
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS | 1 |
Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 3 |
Behrens, L; Capper, D; Purrucker, JC; Veltkamp, R | 1 |
Gonzva, J; Lignac, D; Patricelli, R | 1 |
Bode, C; Haas, S; Norrving, B; Turpie, AG | 1 |
Cloutier, M; Coleman, CI; Damaraju, CV; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Schein, JR | 1 |
Meddahi, S; Samama, MM | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
Giugliano, RP; Reddy, P | 1 |
Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A | 1 |
Thachil, J | 1 |
Hagen, G; Klemp, M; Wisløff, T | 1 |
Hagii, J; Hitomi, H; Kamada, T; Kimura, Y; Metoki, N; Okumura, K; Osanai, T; Saito, S; Shiroto, H; Tomita, H; Yasujima, M | 1 |
Piccini, JP; Steinberg, BA | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Harrell, FE; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
Germain, G; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Raut, MK; Schein, JR | 2 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, R; Fox, KA; Hacke, W; Hankey, GJ; Hu, DY; Mahaffey, KW; Oomman, A; Patel, MR; Singer, DE; Tan, RS; Wong, KS | 1 |
Lip, GY; Yasaka, M | 1 |
Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
Brouns, R; De Keyser, J; De Smedt, A; Jochmans, K; Nieboer, K; van Hooff, RJ; Yperzeele, L | 1 |
Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
Foley, J; Kirchhof, P; Lip, GY | 1 |
Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
Hürlimann, D; Noll, G; Noll, S | 1 |
Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J | 1 |
Chen, H; Higashino, H; Jin, D; Li, W; Miyazaki, M; Okamura, H; Takai, S; Yamamoto, H; Yamanishi, H; Yamanishi, K | 1 |
Freedman, JE; Gersh, BJ | 1 |
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, DM | 1 |
Coleman, CI; Damaraju, CV; Nelson, WW; Schein, JR; Smith, DM; Song, X; Thomson, E | 1 |
Lévy, S | 1 |
Baker, WL; Chamberlin, KW | 1 |
Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
Dan, GA; Kaski, JC; Martínez-Rubio, A | 1 |
Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Kurata, T; Omote, Y; Sato, K; Yamashita, T; Yunoki, T | 1 |
Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P | 1 |
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R | 1 |
Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z | 1 |
Gerona, RR; Lo, JC | 1 |
Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
Baba, Y; Hagii, J; Hitomi, H; Iwata, M; Kamada, T; Matsumoto, S; Metoki, N; Okumura, K; Osanai, T; Saito, S; Sasaki, S; Seino, S; Shiroto, H; Takahashi, K; Tomita, H; Uchizawa, T; Yasujima, M | 1 |
Amarenco, P; Camm, AJ; Haas, S; Hess, S; Kirchhof, P; Turpie, AG; van Eickels, M | 1 |
Mitchell, AR; Page, PL; Thomas, R | 1 |
Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
Bonati, LH; Engelter, ST; Gensicke, H; Lyrer, P; Peters, N; Seiffge, DJ; Traenka, C; Tsakiris, DA | 1 |
Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X | 1 |
Steurer, J | 1 |
Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
Baumgartner, H; Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
Fukae, J; Higashi, T; Inoue, T; Iwaasa, M; Kimura, S; Ogata, T; Okawa, M; Tsuboi, Y | 1 |
Rudakova, AV; Tatarskiĭ, BA | 1 |
Dobesh, PP; Trujillo, T | 1 |
Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, M; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P | 1 |
Lane, DA; Lip, GY; Senoo, K | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA | 1 |
Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
Demulder, A; Safouris, A; Triantafyllou, N; Tsivgoulis, G | 1 |
Giugliano, RP; Plitt, A | 1 |
Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
Lamichhane, D | 1 |
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
Kovács, T | 1 |
Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
Ezekowitz, MD; Kent, AP | 1 |
Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
Choi, YJ; Hong, KS; Kwon, SU | 1 |
Mima, Y; Nagata, S; Okada, Y; Sangatsuda, Y; Wakugawa, Y; Yasaka, M | 1 |
Baber, U; Mastoris, I; Mehran, R | 1 |
Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 3 |
Rondina, M | 1 |
Greco, C | 1 |
Cairns, JA; Weitz, JI | 1 |
Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J | 1 |
Arepally, GM; Ortel, TL | 1 |
Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
Merli, GJ; Weitz, HH | 1 |
Trusler, M | 1 |
Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; Washam, JB | 1 |
Hogg, K; Weitz, JI; Yeh, CH | 1 |
Lane, DA; Wood, K | 1 |
Bambakidis, NC; Barnett, A; Filichia, E; Jin, Y; Luo, Y; Raviv, N | 1 |
Hilpert, U | 1 |
Ay, C; Belik, S; Griesmacher, A; Königsbrügge, O; Pabinger, I; Quehenberger, P; Seger, C; Weigel, G | 1 |
Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H | 1 |
Botto, GL; Colonna, P; Troccoli, R | 1 |
Ichijo, M; Ishibashi, S; Li, F; Miki, K; Mizusawa, H; Yokota, T; Yui, D | 1 |
Ofosu, FA | 1 |
Lasek-Bal, A; Piekarski, M; Puz, P; Urbanek, T | 1 |
Brown, DA; Chang, FL; Curfman, ET; Kuo, PC; Paraiso, HC; Scofield, BA; Yen, JH; Yu, IC | 1 |
Alberts, MJ; Hanley, DF; Serebruany, VL | 1 |
Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD | 1 |
Spyropoulos, AC | 1 |
Culebras, A; Kelly, JJ | 1 |
Haas, S | 1 |
Doggrell, SA | 1 |
Calderone, A; Gillis, MA; Gutkowska, J; Jankowski, M; Menaouar, A; Mukaddam-Daher, S; Paquette, PA; Shi, YF; Tardif, JC | 1 |
Antman, EM; Brandt, JT; Braunwald, E; Close, SL; Hockett, RD; Macias, WL; Mega, JL; Sabatine, MS; Shen, L; Walker, JR; Wiviott, SD | 1 |
Dowlatshahi, D; Hill, MD | 1 |
Avery, A; Boyd, EA; Brunton, SA; Buxton, D; di Lucrezia, R; Guicherit, OM; Kruse, LI; MacKinnon, CH; Park, Y; Price, S; Rubin, LL; Stibbard, JH | 1 |
Diener, HC; Gradl, B; Greiner, W; Jönsson, B; Lindgren, P; Lüders, S; Schrader, J; Schwander, B; Villar, FA; Zöllner, Y | 1 |
Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A | 1 |
Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD | 1 |
Collet, JP; Montalescot, G | 1 |
Hasegawa, Y; Rolland, W; Sozen, T; Suzuki, H; Zhang, JH | 1 |
Lai, CH | 1 |
Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S | 1 |
Khalabuda, M; McBride, BF; Morell, J; Sullivan, B | 1 |
Serebruany, V | 2 |
Lopes, RD; Mahaffey, KW; Piccini, JP | 1 |
Diamond, GA; Kaul, S | 1 |
Pakhomov, IaM | 1 |
Alban, S; Völler, H; Westermann, D | 1 |
Finnerup, NB | 1 |
Baumhäkel, M; Böhm, M; Schirmer, SH | 1 |
Dijkgraaf, MGW; Heesen, M; Hollmann, MW; Kruis, MR; Pijl, AJ; van der Vegt, MH; Vos, K; Vranken, JH | 1 |
Weitz, JI | 1 |
Mitka, M | 2 |
Aumiller, J | 1 |
Ahrens, I; Lip, GY; Peter, K | 1 |
Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
Ageno, W; Romualdi, E | 1 |
Braunwald, E; Steffel, J | 1 |
Easton, JD | 1 |
Ajzenberg, N; Dumont, B; Faille, D | 1 |
Alexopoulos, D; Davlouros, P; Dimitropoulos, G; Hahalis, G; Mylona, P; Panagiotou, A; Perperis, A; Tsigkas, G; Xanthopoulou, I | 1 |
Brott, BC; Dobbs, JC; Hillegass, WB; Misra, VK; Papapietro, SE; Zoghbi, GJ | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Pan, G; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE | 1 |
Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J | 1 |
Mega, JL | 1 |
Becker, RC; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, D | 1 |
Mousa, SA | 1 |
Agnelli, G; Decousus, H; Lensing, AW; Misselwitz, F; Mueck, W; Prandoni, P | 1 |
Camaioni, E; Chen, Y; Chiarugi, A; Cozzi, A; Formentini, L; Gonzales, C; Liang, S; Moroni, F; Pellegrini-Giampietro, DE; Pellicciari, R; Wood, A; Zaleska, MM | 1 |
Bode, C; Diener, HC; Kaeufer, T | 1 |
Leibowitz, A; Paradis, P; Rautureau, Y; Rehman, A; Schiffrin, EL; Yamamoto, N | 1 |
Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
Nagao, T | 1 |
Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ | 1 |
Parma, Z; Syzdół, M; Tendera, M | 1 |
Bergmann, P; Body, JJ; Boonen, S; Devogelaer, JP; Gielen, E; Goemaere, S; Kaufman, JM; Reginster, JY; Rozenberg, S | 1 |
Alpert, JS | 1 |
Lip, GY; Riva, N | 1 |
Gorelick, PB | 1 |
Becker, RC; Breithardt, G; Califf, RM; Carolei, A; Diener, HC; Donnan, GA; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Mas, JL; Massaro, A; Nessel, CC; Norrving, B; Paolini, JF; Patel, MR; Roine, RO; Singer, DE; Stevens, SR; Wong, L | 1 |
Palareti, G; Tripodi, A | 1 |
Bryer, A | 1 |
Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
Haas, S; Schellong, SM; Spannagl, M | 1 |
Gibson, CM; Gopalakrishnan, L; Kohli, P; Kumar, V; Rastogi, U; Singh, P | 1 |
Bommer, WJ | 1 |
Halperin, JL; Varughese, CJ | 1 |
Lewalter, T | 1 |
Anglade, MW; Coleman, CI; Kluger, J; Lee, S; Pham, D; Pisacane, R | 1 |
Goto, S; Hori, M; Iwamoto, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H | 3 |
Ismael, AG; Ribowsky, JH | 1 |
Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
Ansell, J; Mantha, S | 1 |
Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC | 1 |
Cohen, D; Gorgoraptis, N; Greenwood, R; Hadji-Michael, M; Husain, M; Kulinskaya, E; Machner, B; Mah, YH; Malhotra, P; Nair, A; Simister, R; Singh-Curry, V; Ward, N | 1 |
Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
Pollack, CV | 1 |
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY | 1 |
Fareed, J; Kalodiki, E; Lewis, B | 1 |
Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C | 1 |
Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
Ji, H; Lai, Y; Li, T; Ling, J; Liu, J; Peng, S; Tian, J; Wang, X; Wu, J; Zhang, Y | 1 |
Berthold, HK | 1 |
Atar, D; Serebruany, VL | 1 |
Zhang, S | 1 |
Yasaka, M | 1 |
Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
Ahrens, I; Bode, C | 1 |
Griffiths, M; Scully, C | 1 |
Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
Cannon, CP; Kohli, P | 1 |
Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ | 1 |
Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
Kopecky, S | 1 |
Brouwers, PJ; Kappelle, LJ; Koudstaal, PJ; Roos, YB; van Dijk, EJ | 1 |
Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
Rajappan, K | 1 |
Esmon, CT | 1 |
Le Heuzey, JY | 1 |
Eikelboom, JW; Manolakos, JJ; Paikin, JS | 1 |
Graf, L; Tsakiris, DA | 1 |
Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S | 1 |
Becker, RC; Chan, MY; Cyr, D; Kajikawa, M; Lin, M; Lucas, J; Moseley, A; Ortel, TL; Thompson, JW; Ueda, H | 1 |
Sanaei, O | 1 |
Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
Aalbers, J | 1 |
Valle Bernad, R | 1 |
Blanco-Molina, A | 1 |
Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C | 1 |
Lipták, J | 1 |
Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
Lazo-Langner, A; Sun, D | 1 |
Dabitz, R; Ochs, G | 1 |
Boehlen, F; de Moerloose, P | 1 |
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K | 1 |
Martin, EN; Money, SR; Shamoun, FE | 1 |
Coccheri, S; Orlando, D | 1 |
Li, HF; Zhao, RL | 1 |
Medvegy, M; Simonyi, G | 1 |
Deitelzweig, SB | 1 |
Eraso, LH; Merli, GJ; Perez, A | 1 |
Camm, AJ; Savelieva, I | 1 |
Greenspon, AJ | 1 |
Ganetsky, V; Spinler, SA; Thomas, TF | 1 |
Shiga, T | 1 |
Grove, EL; Husted, SE; Kraglund, KL; Modrau, B | 1 |
Brem, E; Foran, M; Koyfman, A | 1 |
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Mohanty, S; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Zhang, Z | 1 |
Reynolds, MR | 1 |
Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW | 1 |
Boĭko, AN; Gusev, EI; Makarov, AN; Martynov, MIu; Petukhov, EB | 1 |
Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W | 1 |
Basile, J; Bloch, MJ | 1 |
Boulanger, JM; Hill, MD | 1 |
Strauss, MH; Verma, S | 1 |
Boysen, G; Hornnes, N; Larsen, K | 1 |
Johnston, SC | 1 |
de la Sierra, A | 1 |
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD | 1 |
Ram, CV; Rudmann, MA | 1 |
Shlyakhto, E | 1 |
Rupp, H | 1 |
Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP | 1 |
Alvarez, W | 1 |
Cregan, E; Macdonald, JE; McCarthy, DJ; Reif, DW | 1 |
Chapman, DF; Lapchak, PA; Zivin, JA | 1 |
Asahi, K; Asahi, M; del Zoppo, GJ; Fini, ME; Jung, JC; Lo, EH | 1 |
Barone, FC; Brooks, DP; Campbell, WG; Chandra, S; Coatney, RW; Contino, LC; Nelson, AH; Ohlstein, EH; Sarkar, SK; Willette, RN | 1 |
Abrahamsen, CT; Barone, FC; Brooks, DP; Campbell, WG; Contino, LC; Edwards, RM; Grygielko, ET; Laping, NJ; Nelson, AH; Pullen, MA | 1 |
143 review(s) available for thiophenes and Stroke
Article | Year |
---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium | 2019 |
Novel synaptic plasticity enhancer drug to augment functional recovery with rehabilitation.
Topics: Animals; Brain Injuries; Combined Modality Therapy; Exercise Therapy; Humans; Intercellular Signaling Peptides and Proteins; Maleates; Nerve Tissue Proteins; Neurological Rehabilitation; Neuronal Plasticity; Neuroprotective Agents; Recovery of Function; Stroke; Thiophenes | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Medication Adherence; Morpholines; Renal Insufficiency; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[The role of internal medicine in preventing stroke in atrial fibrillation].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Advances in the secondary prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes | 2012 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload | 2013 |
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Drug Interactions; Embolism; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in gastroenterology practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Prevention of stroke in patients with atrial fibrillation: a role of modern anticoagulants].
Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants: a focused review for stroke physicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Child; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Administration Schedule; Drug Interactions; Drug Substitution; Hemorrhage; Humans; Morpholines; Patient Selection; Perioperative Care; Practice Guidelines as Topic; Preventive Health Services; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzamides; Blood Coagulation; Embolism; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia; Thrombosis | 2014 |
The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
Atrial fibrillation - new frontiers in anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.
Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hip Joint; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
Update on secondary prevention of ischaemic stroke.
Topics: Anticoagulants; Blood Coagulation; Brain Ischemia; Foramen Ovale, Patent; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Ventricular Dysfunction, Left | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Brave new world: the current and future use of novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Topics: Anticoagulants; Antithrombin III; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2009 |
New findings with old drugs for osteoporosis.
Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Norpregnenes; Organometallic Compounds; Osteoporosis, Postmenopausal; Stroke; Thiophenes | 2009 |
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2010 |
[New oral anticoagulants: better than vitamin K antagonists?].
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K | 2010 |
[Novel anticoagulants for stroke prevention in atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2010 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drugs, Investigational; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Venous Thromboembolism | 2011 |
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombosis; Time Factors; Treatment Outcome | 2011 |
[Atrial fibrillation: what the GP needs to know].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2011 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Current status and future of anti-Xa inhibitors].
Topics: Anticoagulants; Atrial Fibrillation; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2011 |
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Drugs, Investigational; Factor X; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants--key messages for the angiologist.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism | 2012 |
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Interactions; Factor Xa; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Myocardial Infarction; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thrombosis | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New oral anticoagulants in the ED setting: a review.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Female; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Approval; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[New oral anticoagulants for atrial fibrillation: a neurologist's view].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
Topics: Anticoagulants; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Anticoagulant treatment: the end of the old agents?
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2012 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
[Stroke risk--atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
[Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Administration Schedule; Humans; International Normalized Ratio; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2013 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Rivaroxaban: an oral factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2013 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Effects of eprosartan on target organ protection.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Endothelium, Vascular; Humans; Hypertension; Imidazoles; Neuroprotective Agents; Nitrendipine; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2006 |
Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Cognition Disorders; Female; Humans; Hypertension; Imidazoles; Male; Sensitivity and Specificity; Severity of Illness Index; Stroke; Survival Analysis; Systole; Thiophenes; Treatment Outcome | 2007 |
Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Dementia, Vascular; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Neuropsychological Tests; Rats; Stroke; Thiophenes | 2007 |
Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Catecholamines; Humans; Hypertension; Imidazoles; Norepinephrine; Stroke; Tetrazoles; Thiophenes; Valine; Valsartan | 2007 |
Rivaroxaban, an oral direct factor Xa inhibitor.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin | 2008 |
61 trial(s) available for thiophenes and Stroke
Article | Year |
---|---|
[Rivaroxaban in prevention of stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome | 2018 |
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Multivariate Analysis; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Topics: Aged; Anticoagulants; Asia; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Europe; Female; Healthcare Disparities; Humans; International Normalized Ratio; Linear Models; Male; Morpholines; Multivariate Analysis; North America; Predictive Value of Tests; Residence Characteristics; Rivaroxaban; South Africa; South America; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2013 |
Prophylactic effects of duloxetine on post-stroke depression symptoms: an open single-blind trial.
Topics: Aged; Antidepressive Agents; Depression; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Single-Blind Method; Stroke; Thiophenes | 2013 |
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Clinical Protocols; Continuity of Patient Care; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Proportional Hazards Models; Research Design; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.
Topics: Acute Coronary Syndrome; Aged; Antibodies, Antiphospholipid; Factor Xa Inhibitors; Female; Humans; Immunoglobulin M; Male; Middle Aged; Morpholines; Myocardial Infarction; Phosphorylcholine; Rivaroxaban; Stroke; Thiophenes | 2014 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; China; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Primary Prevention; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.
Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Male; Morpholines; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Pressure; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Vitamin K; Warfarin | 2014 |
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome | 2014 |
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stro
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Blood Transfusion; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Plasma; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2014 |
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in at
Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Black People; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Embolism; Europe; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; North America; Point-of-Care Systems; Predictive Value of Tests; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Asia, Eastern; Asian People; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine | 2014 |
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Topics: Africa; Atrial Fibrillation; Clinical Protocols; Europe; Factor Xa Inhibitors; Humans; Latin America; Middle East; Morpholines; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Rivaroxaban; Sample Size; Stroke; Thiophenes; Time Factors; Treatment Outcome | 2014 |
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mitral Valve Insufficiency; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K | 2014 |
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2015 |
Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Research Design; Rivaroxaban; Stroke; Thiophenes | 2015 |
Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Morpholines; Prothrombin Time; Rivaroxaban; Stroke; Thiophenes | 2015 |
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome | 2015 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome | 2009 |
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine | 2009 |
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Medical Records; Morpholines; Research Design; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2010 |
Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Disability Evaluation; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Hyperalgesia; Male; Middle Aged; Neuralgia; Outcome Assessment, Health Care; Pain Measurement; Pain Threshold; Placebo Effect; Spinal Cord Injuries; Stroke; Thiophenes; Treatment Outcome | 2011 |
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2011 |
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2011 |
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Weight; Computer Simulation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Young Adult | 2011 |
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Morpholines; Multicenter Studies as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke.
Topics: Adult; Aged; Aged, 80 and over; Dopamine Agonists; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Perceptual Disorders; Psychomotor Performance; Stroke; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome; Young Adult | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine | 2012 |
Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Depression; Duloxetine Hydrochloride; Fatigue; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Sertraline; Stroke; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2012 |
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Proteins; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Proteomics; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa; Female; Follow-Up Studies; Humans; Incidence; Male; Morpholines; Predictive Value of Tests; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Kidney; Male; Middle Aged; Morpholines; Renal Insufficiency; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Morpholines; Outcome Assessment, Health Care; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Time Factors; Warfarin; Withholding Treatment | 2013 |
[Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Topics: Acrylates; Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Chi-Square Distribution; Data Interpretation, Statistical; Diastole; Female; Hemodynamics; Humans; Hypertension; Imidazoles; Male; Middle Aged; Quality of Life; Recurrence; Stroke; Systole; Thiophenes; Time Factors | 2003 |
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Calcium; Cardiovascular Diseases; Female; Humans; Hypertension; Imidazoles; Magnetic Resonance Spectroscopy; Male; Middle Aged; Nitrendipine; Prospective Studies; Recurrence; Risk Factors; Single-Blind Method; Sodium Chloride Symporter Inhibitors; Stroke; Thiophenes; Time Factors; Treatment Outcome | 2005 |
Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Data Interpretation, Statistical; Diuretics; Humans; Imidazoles; Internal Medicine; Ischemic Attack, Transient; Morbidity; Neurology; Nitrendipine; Prospective Studies; Stroke; Thiophenes | 2006 |
MOSES raises questions.
Topics: Acrylates; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Statistical; Humans; Imidazoles; Ischemic Attack, Transient; Nitrendipine; Research Design; Risk Factors; Stroke; Thiophenes | 2006 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2007 |
Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Topics: Acrylates; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; Cognition Disorders; Dementia, Vascular; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Neuropsychological Tests; Rats; Stroke; Thiophenes | 2007 |
192 other study(ies) available for thiophenes and Stroke
Article | Year |
---|---|
Stimulation of angiotensin II receptor 2 preserves cognitive function and is associated with an enhanced cerebral vascular density after stroke.
Topics: Animals; Cognition; Female; Imidazoles; Male; Microvascular Density; Rats; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Stroke; Sulfonamides; Thiophenes | 2021 |
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Humans; Intention to Treat Analysis; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2021 |
Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Bilirubin; China; Factor Xa Inhibitors; Humans; Morpholines; Nucleotides; Prospective Studies; Rivaroxaban; Stroke; Thiophenes | 2022 |
Direct AT2R Stimulation Slows Post-stroke Cognitive Decline in the 5XFAD Alzheimer's Disease Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognitive Dysfunction; Disease Models, Animal; Humans; Imidazoles; Mice; Mice, Transgenic; Neurodegenerative Diseases; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Thiophenes | 2022 |
Contralesional angiotensin type 2 receptor activation contributes to recovery in experimental stroke.
Topics: Animals; Diabetes Mellitus, Experimental; Imidazoles; Infarction, Middle Cerebral Artery; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Thiophenes | 2022 |
Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization.
Topics: Animals; Cell Polarity; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diet, High-Fat; Imidazoles; Male; Microglia; Rats, Wistar; Receptor, Angiotensin, Type 2; Streptozocin; Stroke; Sulfonamides; Thiophenes | 2020 |
Two Mixed-ligand Coordination Polymers: Crystal Structures and Protective Effect on Ischemic Stroke by Increasing glp1r Expression.
Topics: Animals; Brain; Chemical Phenomena; Cognition; Coordination Complexes; Crystallization; Endothelial Cells; Gene Expression; Glucagon-Like Peptide-1 Receptor; Imidazoles; Ligands; Maze Learning; Metals; Mice; Models, Molecular; Molecular Conformation; Polymers; Stroke; Structure-Activity Relationship; Thiophenes; X-Ray Diffraction | 2020 |
A Stretchable and Transparent Electrode Based on PEGylated Silk Fibroin for In Vivo Dual-Modal Neural-Vascular Activity Probing.
Topics: Animals; Brain-Computer Interfaces; Disease Models, Animal; Elastic Modulus; Electric Conductivity; Electrodes; Electrodes, Implanted; Electronics; Electrophysiology; Epoxy Resins; Fibroins; Hydrogels; Polystyrenes; Pressure; Rats; Silk; Spectroscopy, Fourier Transform Infrared; Stress, Mechanical; Stroke; Thiophenes | 2021 |
Present status and future orientation of rivaroxaban application in patients with nonvulvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2017 |
Protective effects of the angiotensin II AT
Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Drug Administration Routes; Drug Delivery Systems; Humans; Male; Nasal Mucosa; Neuroprotective Agents; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Thiophenes | 2018 |
Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Fibrinolytic Agents; Male; Random Allocation; Rats; Rats, Wistar; Recovery of Function; Stroke; Sulfonamides; Thiophenes; Thromboembolism; Tissue Plasminogen Activator | 2019 |
CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage.
Topics: Animals; Brain Injuries; Intercellular Signaling Peptides and Proteins; Male; Maleates; Mice; Mice, Knockout; Mice, Mutant Strains; Motor Cortex; Nerve Tissue Proteins; Neuronal Plasticity; Neuroprotection; Quality of Life; Receptors, AMPA; Recovery of Function; Stroke; Thiophenes | 2018 |
Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals-A randomized double- blind pre-clinical study.
Topics: Administration, Oral; Aging; Animals; Body Weight; Cognitive Dysfunction; Disease Models, Animal; Double-Blind Method; Drug Evaluation, Preclinical; Male; Motor Activity; Nootropic Agents; Random Allocation; Rats, Wistar; Receptor, Angiotensin, Type 2; Recovery of Function; Stroke; Sulfonamides; Thiophenes; Time Factors | 2019 |
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Female; Geriatric Assessment; Hospitalization; Humans; Inpatients; Male; Movement; Parkinson Disease, Secondary; Patient Safety; Prospective Studies; Quality of Life; Risk Assessment; Sampling Studies; Severity of Illness Index; Stroke; Tetrahydronaphthalenes; Thiophenes; Time Perception; Transdermal Patch; Treatment Outcome | 2019 |
Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Mice; Oxazoles; PPAR alpha; PPAR gamma; Stroke; Thiophenes | 2019 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
Involvement of matrix metalloproteinases-2 and -9 in the formation of a lacuna-like cerebral cavity.
Topics: Analysis of Variance; Animals; CD11b Antigen; Disease Models, Animal; Ectodysplasins; Gene Expression Regulation, Enzymologic; Glial Fibrillary Acidic Protein; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microglia; Minocycline; Phenylalanine; Protease Inhibitors; Rats; Rats, Wistar; Stroke; Stroke, Lacunar; Thiophenes; Time Factors | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
[Comparison of the therapeutic effect of the Warfarin and Rivaroksaban among the patients with not-valuate fibrillation of atrium].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
The J-ROCKET AF study: a matter of ethnicity or a matter of weight?
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin | 2013 |
The J-ROCKET AF Study: a matter of ethnicity or a matter of weight? Reply.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Warfarin | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Differential therapy with the new anticoagulants, 5].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2013 |
Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Fact
Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K | 2013 |
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inh
Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K | 2013 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Topics: Anticoagulants; Atrial Fibrillation; Belgium; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Humans; Markov Chains; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin | 2014 |
Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Stroke and urosepsis after discontinuation of rivaroxaban.
Topics: Aged, 80 and over; Anticoagulants; Humans; Male; Morpholines; Rivaroxaban; Sepsis; Stroke; Thiophenes; Urinary Tract Infections | 2013 |
Dissolution of the left atrial appendage thrombus with rivaroxaban therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thrombosis; Treatment Outcome | 2013 |
Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment.
Topics: Administration, Intravenous; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Contraindications; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Ischemia; Middle Cerebral Artery; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2014 |
[Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Substitution; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
[How to properly use warfarin and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Humans; International Normalized Ratio; Morpholines; Practice Guidelines as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
Topics: Animals; Anticoagulants; Blood-Brain Barrier; Brain Ischemia; Cerebral Hemorrhage; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Morpholines; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Time Factors | 2014 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment | 2014 |
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.
Topics: Aged; Anticoagulants; Blood Coagulation; Factor XI; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombolytic Therapy | 2014 |
The risk of infection with new oral anticoagulants: a meta-analysis.
Topics: Anticoagulants; Humans; Male; Morpholines; Sepsis; Stroke; Thiophenes; Urinary Tract Infections | 2014 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2014 |
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Brain Infarction; Brain Ischemia; CD11b Antigen; Cerebrovascular Circulation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Glial Fibrillary Acidic Protein; Imidazoles; Male; Nitric Oxide Synthase Type II; Peroxidase; Pyridines; Rats; Rats, Sprague-Dawley; Stroke; Sulfonamides; Thiophenes; Time Factors | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy.
Topics: Aged; Anticoagulants; Brain; Cerebral Hemorrhage; Fatal Outcome; Female; Hematoma, Subdural, Intracranial; Humans; Morpholines; Neuroimaging; Rivaroxaban; Stroke; Thiophenes; Tomography, X-Ray Computed | 2014 |
Spontaneus splenic rupture in a patient treated with rivaroxaban.
Topics: Abdominal Pain; Aged; Anticoagulants; Atrial Fibrillation; Emergency Service, Hospital; Humans; Male; Morpholines; Rivaroxaban; Rupture, Spontaneous; Shock, Hemorrhagic; Splenic Diseases; Stroke; Thiophenes | 2014 |
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin; Young Adult | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient.
Topics: Aged; Echocardiography, Transesophageal; Embolism; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Treatment Outcome | 2014 |
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Databases, Factual; Female; Hospital Costs; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Morpholines; Propensity Score; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin; Young Adult | 2014 |
Stroke prevention in Asian patients with atrial fibrillation.
Topics: Anticoagulants; Asian People; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban.
Topics: Aged, 80 and over; Brain Ischemia; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Morpholines; Polypharmacy; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Body Weight; Chymases; Endothelium, Vascular; Hypertension; Male; Matrix Metalloproteinase 9; Myocardium; Rats; Rats, Inbred SHR; Renin; RNA, Messenger; Stroke; Sulfonamides; Systole; Thiophenes | 2014 |
Atrial fibrillation and stroke prevention in aging patients: what's good can be even better.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Databases, Factual; Female; Humans; Male; Medication Adherence; Middle Aged; Morpholines; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
Topics: Animals; Anticoagulants; Blood Coagulation; Brain; Brain Ischemia; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Morpholines; Pyrazoles; Pyridones; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator | 2014 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2014 |
A case of rivaroxaban associated intracranial hemorrhage.
Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Fatal Outcome; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
Intravenous thrombolysis in stroke patients receiving rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Revascularization for acute ischemic stroke is safe for rivaroxaban users.
Topics: Aged, 80 and over; Brain Ischemia; Cerebral Revascularization; Factor Xa Inhibitors; Female; Humans; Infarction, Middle Cerebral Artery; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombectomy; Tissue Plasminogen Activator | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Socioeconomic Factors; Stroke; Thiophenes; Warfarin | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Acute thrombocytopenia after initiating anticoagulation with rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombocytopenia; Warfarin | 2014 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
[Rivaroxaban in non valvular atrial fibrillation: subgroups analysis].
Topics: Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Web Exclusives. The consult guys--too close for comfort? For how long must I stop this anticoagulant for an epidural?
Topics: Adrenal Cortex Hormones; Aged; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Humans; Injections, Epidural; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin; Withholding Treatment | 2015 |
Response.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes; Venous Thromboembolism | 2015 |
Well-managed warfarin is superior to NOACs.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes; Venous Thromboembolism | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Death, Sudden; Diabetes Mellitus; Digoxin; Factor Xa Inhibitors; Female; Heart Failure; Heart Rate; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Sex Distribution; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
The shh signaling pathway is upregulated in multiple cell types in cortical ischemia and influences the outcome of stroke in an animal model.
Topics: Animals; Behavior, Animal; Brain Ischemia; Cerebral Cortex; Cyclohexylamines; Hedgehog Proteins; Male; Mice; Signal Transduction; Stroke; Tamoxifen; Thiophenes | 2015 |
[Prevention and emergency measures].
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2015 |
Rivaroxaban 10mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic disease.
Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Morpholines; Recurrence; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes | 2015 |
[The X-VeRT study].
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Middle Aged; Morpholines; Multicenter Studies as Topic; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2015 |
Sphingosine-1-Phosphate Receptor-1 Selective Agonist Enhances Collateral Growth and Protects against Subsequent Stroke.
Topics: Animals; Dimethyl Sulfoxide; Disease Models, Animal; Endothelial Cells; Male; Mice; Oxadiazoles; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Stroke; Thiophenes; Time Factors | 2015 |
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes.
Topics: Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine | 2015 |
Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients".
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Follow-Up Studies; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2016 |
3H-1,2-Dithiole-3-thione as a novel therapeutic agent for the treatment of ischemic stroke through Nrf2 defense pathway.
Topics: Animals; Antioxidants; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Mice; NF-E2-Related Factor 2; Reactive Oxygen Species; Signal Transduction; Stroke; Thiones; Thiophenes | 2017 |
Sleep disorders and neuromuscular diseases.
Topics: Administration, Cutaneous; Brain Injuries; Continuous Positive Airway Pressure; Copper; Diabetic Neuropathies; Dopamine Agonists; Humans; Ischemic Attack, Transient; Myasthenia Gravis; Neuromuscular Diseases; Peripheral Nervous System Diseases; Restless Legs Syndrome; Sleep Apnea Syndromes; Sleep Wake Disorders; Stroke; Tetrahydronaphthalenes; Thiophenes | 2008 |
Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
Topics: Acrylates; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Heart Rate; Hypertension; Imidazoles; Male; Nitric Oxide Synthase Type III; Phosphorylation; Rats; Rats, Inbred SHR; Stroke; Thiophenes; Ventricular Function, Left | 2009 |
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Diseases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Male; Microsomes, Liver; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Treatment Outcome; Young Adult | 2009 |
Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hypertension; Imidazoles; Ischemic Attack, Transient; Male; Nitrendipine; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thiophenes | 2009 |
Potent agonists of the Hedgehog signaling pathway.
Topics: Administration, Oral; Animals; Carboxylic Acids; Cell Line; Chemistry, Pharmaceutical; Drug Design; Hedgehog Proteins; Humans; Mice; Models, Biological; Models, Chemical; Stroke; Structure-Activity Relationship; Thiophenes | 2009 |
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Topics: Acrylates; Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Enalapril; Europe; Geography; Humans; Hypertension; Imidazoles; Male; Meta-Analysis as Topic; Middle Aged; Monte Carlo Method; Nitrendipine; Primary Prevention; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Thiophenes | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Fingolimod Hydrochloride; Immunosuppressive Agents; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; MAP Kinase Signaling System; Nerve Degeneration; Neuroprotective Agents; Oxadiazoles; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Stroke; Thiophenes; Treatment Outcome | 2010 |
Duloxetine related hypersexuality: a case report.
Topics: Adult; Duloxetine Hydrochloride; Humans; Hypertension; Male; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Stroke; Thiophenes | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States | 2010 |
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Blood Coagulation Disorders; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2010 |
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Colorectal Neoplasms; Humans; Incidence; Lung Neoplasms; Mice; Myocardial Infarction; Neoplasms, Experimental; Piperazines; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2 Receptor Antagonists; Risk Factors; Stroke; Thiophenes; United States | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Is duloxetine useful for central neuropathic pain?
Topics: Duloxetine Hydrochloride; Female; Humans; Male; Neuralgia; Spinal Cord Injuries; Stroke; Thiophenes | 2011 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
New alternative to warfarin may help reduce stroke risk in patients with AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Approval; Humans; Morpholines; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2011 |
[Rivaroxaban at least as effective as marcumar in stroke prevention].
Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Humans; International Normalized Ratio; Morpholines; Multicenter Studies as Topic; Phenprocoumon; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes | 2010 |
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2011 |
Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Thiophenes | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
The future of anticoagulant therapy.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Drug Approval; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Enzyme Inhibitors; Female; HeLa Cells; Humans; Infarction, Middle Cerebral Artery; Isoquinolines; Male; Motor Activity; Neuroprotective Agents; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stroke; Thiophenes; Tumor Cells, Cultured | 2012 |
FDA advisory decision highlights some problems inherent in pragmatic trials.
Topics: Advisory Committees; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Approval; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration; Warfarin | 2011 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2012 |
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Collagen; Disease Models, Animal; Fibronectins; Fibrosis; Hypertension; Losartan; Macrophages; Male; Myocardium; Oxidative Stress; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 2; Stroke; Sulfonamides; Superoxides; Thiophenes; Vascular Stiffness | 2012 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium; Cardiovascular Diseases; Consensus; Denosumab; Dietary Supplements; Diphosphonates; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Neoplasms; Organometallic Compounds; Osteoporosis; Selective Estrogen Receptor Modulators; Stroke; Thiophenes; Vitamin D | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Rivaroxaban and recurrent stroke prevention in AF.
Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Markov Chains; Medicare; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2012 |
Oral anticoagulants for atrial fibrillation: Which one to choose?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA?
Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Stroke; Thiophenes; Warfarin | 2012 |
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Free Radical Scavengers; Male; Neuroprotective Agents; PC12 Cells; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Stereoisomerism; Stroke; Structure-Activity Relationship; Thiophenes | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Danger ahead: watch out for indirect comparisons!
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Female; Forecasting; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
How big is the impact of the warfarin cost on the cost-effectiveness of rivaroxoban for stroke prevention in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Stroke; Thiophenes; Warfarin | 2012 |
Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Electrocardiography; Expert Testimony; Humans; Morpholines; Myocardial Infarction; Practice Guidelines as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Rivaroxaban versus warfarin: results of the ROCKET study].
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Humans; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
New oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Reply: To PMID 22575324.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes | 2013 |
Lack of stroke subtype information may hinder indirect comparison between the ROCKET-AF and other trials of new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes | 2013 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
"R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation.
Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Reconsideration of anticoagulant therapy in Japanese patients with atrial fibrillation and moderate renal impairment.
Topics: Anticoagulants; Asian People; Atrial Fibrillation; Female; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes | 2013 |
Discontinuation of rivaroxaban: filling in the gaps.
Topics: Atrial Fibrillation; Blood Coagulation; Female; Humans; Male; Morpholines; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Therapy of hypertension. Why the systolic value is decisive].
Topics: Acrylates; Antihypertensive Agents; Coronary Disease; Enalapril; Humans; Hypertension; Imidazoles; Risk Factors; Stroke; Systole; Thiophenes; Treatment Outcome | 2002 |
Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Humans; Hypertension; Imidazoles; Nitrendipine; Randomized Controlled Trials as Topic; Stroke; Survival Rate; Thiophenes | 2005 |
Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Humans; Imidazoles; Nitrendipine; Randomized Controlled Trials as Topic; Stroke; Thiophenes | 2006 |
Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Follow-Up Studies; Humans; Imidazoles; Multicenter Studies as Topic; Nitrendipine; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Treatment Outcome | 2006 |
[Not all antihypertensive agents protect equally well].
Topics: Acrylates; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; Follow-Up Studies; Humans; Hypertension; Imidazoles; Meta-Analysis as Topic; Nitrendipine; Primary Prevention; Risk Factors; Stroke; Thiophenes; Time Factors | 2006 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine | 2008 |
[Stroke prevention. Is there an added value to RAS inhibition?].
Topics: Acrylates; Animals; Antihypertensive Agents; Humans; Hypertension; Imidazoles; Randomized Controlled Trials as Topic; Rats; Stroke; Thiophenes | 2000 |
Discovery and development of neuronal nitric oxide synthase inhibitors.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Dogs; Drug Design; Enzyme Inhibitors; Humans; Isoquinolines; Kinetics; Macaca fascicularis; Male; Mice; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Rats; Stroke; Tetrahydroisoquinolines; Thiophenes | 2000 |
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Fibrinolytic Agents; Humans; Intracranial Embolism; Metalloendopeptidases; Phenylalanine; Protease Inhibitors; Rabbits; Stroke; Thiophenes; Thromboembolism; Tissue Plasminogen Activator | 2000 |
Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.
Topics: Animals; Brain; Brain Ischemia; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Phenylalanine; Protease Inhibitors; Stroke; Thiophenes; Transcription, Genetic | 2000 |
Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Topics: Acrylates; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Cardiomegaly; Heart Rate; Hypertension; Imidazoles; Kidney; Magnetic Resonance Imaging; Male; Myocardium; Natriuresis; Organ Size; Peptide Fragments; Protein Precursors; Proteinuria; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Thiophenes; Ventricular Remodeling | 2001 |
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blotting, Western; Body Weight; Dietary Fats; Disease Progression; Extracellular Matrix; Fibrinolysin; Gene Expression Regulation; Heart Rate; Hypertension; Imidazoles; Kidney Diseases; Male; Organ Size; Plasminogen Activator Inhibitor 1; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Serine Proteinase Inhibitors; Sodium Chloride, Dietary; Stroke; Thiophenes; Thrombosis | 2002 |